期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 92, 期 1, 页码 112-117出版社
WILEY
DOI: 10.1038/clpt.2012.57
关键词
-
资金
- National Institutes of Health [R01DK080007, U01HL069757, U19HL065962, U01HG006378, K23HL086556, R24 GM61374]
- Swedish Research Council [Medicine 523-2008-5568]
- Swedish Heart and Lung Foundation
- EU [HEALTH-F2-2009-223062]
- Clinical Research Support (ALF) at Uppsala University
- Sigrid Juselius Foundation (Helsinki, Finland)
- Helsinki University Central Hospital (Helsinki, Finland)
- European Research Council (Brussels, Belgium)
Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据